Related Experiment Video
Updated: Mar 25, 2026

Cholesterol Efflux Assay
Published on: March 6, 2012
Increased statin eligibility based on ACC/AHA versus NCEP guidelines for high cholesterol management in Chile
Guadalupe Echeverría1, Catalina Dussaillant2, Luis Villarroel3
1Centre for Molecular Nutrition and Chronic Diseases, Pontificia Universidad Católica de Chile, Santiago, Chile.
Insights
New cardiovascular guidelines significantly increased statin eligibility in Chile. The American College of Cardiology and American Heart Association (ACC/AHA) recommendations expanded statin therapy for more women and older adults compared to older National Cholesterol Education Program (NCEP) guidelines.
Area of Science:
- Cardiology
- Public Health
- Epidemiology
Background:
- The 2013 American College of Cardiology and American Heart Association (ACC/AHA) guidelines updated cardiovascular risk assessment and cholesterol management.
- These guidelines modified previous recommendations from the National Cholesterol Education Program (NCEP) established in 2001.
- The impact of the new ACC/AHA guidelines on statin eligibility in Latin America remained unquantified.
Purpose of the Study:
- To estimate and compare statin therapy eligibility in the adult Chilean population using ACC/AHA and NCEP guidelines.
- To assess the impact of updated cardiovascular guidelines on potential statin use in Chile.
Main Methods:
- Cross-sectional analysis of a representative Chilean adult sample from the 2009-2010 National Health Survey (NHS).
- Calculation of the proportion of individuals eligible for statin therapy under both ACC/AHA and NCEP guidelines.
Main Results:
- ACC/AHA guidelines increased statin eligibility from 21.7% (NCEP) to 33.2% (a 53% rise).
- The increase was more pronounced in women (29.6% vs. 15.6%) and individuals over 60 (75% vs. 46%).
- Newly eligible individuals under ACC/AHA included more women, older adults, and those with lower LDL cholesterol.
Conclusions:
- The new ACC/AHA guidelines substantially increased the number of Chilean adults eligible for statin therapy compared to NCEP.
- Implementation of ACC/AHA guidelines has significant public health implications for Chile and potentially other Latin American countries.
- Expanded eligibility includes more women and older adults without diagnosed cardiovascular disease, warranting further consideration.
Background:
In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) jointly released new guidelines for cardiovascular risk assessment and cholesterol management that substantially modified the previous recommendations proposed by the National Cholesterol Education Program (NCEP) in 2001. The relative impact of these new guidelines on potential statin use has not been estimated in Latin American populations.
Objective:
To estimate and compare eligibility for statin therapy based on ACC/AHA and NCEP guidelines in adult Chilean population.
Methods:
Using data from the last National Health Survey (2009-2010 NHS), we conducted a cross-sectional analysis in a representative sample of the Chilean adult population and calculated the proportion of individuals that would receive statins under each set of guidelines.
Results:
According to ACC/AHA guidelines, the population eligible for statin treatment increased from 21.7% (NCEP guidelines) to 33.2% (overall 53% increase). This effect was more pronounced among women (29.6% under ACC/AHA vs 15.6% under NCEP) and with those of advanced age (75% of the subjects >60 years of age compared with 46% under NCEP). The newly eligible group included more women and older subjects and individuals with lower LDL cholesterol levels.
Conclusion:
Compared with NCEP recommendations, the new ACC/AHA guidelines significantly increased the number of Chilean adults eligible for statin therapy. Full implementation of the new recommendations may have important public health implications in Chile and other Latin American countries, as more women and older subjects without cardiovascular disease would qualify for statin treatment.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Angina IV: Management
Coronary Artery Disease IV: Preventive Measures
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease V: Interprofessional Care

